A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes

NCT06385327 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

115

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Genital Herpes Simplex Type 2

Interventions

DRUG: ABI-5366
DRUG: ABI-5366 Placebo

Sponsor

Assembly Biosciences